- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | Pyxis Oncology, Inc. - 10-Q, Quarterly Report | 8 | SEC Filings | ||
| 13.08. | Pyxis Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | Pyxis Oncology GAAP EPS of -$0.40 misses by $0.05 | 2 | Seeking Alpha | ||
| PYXIS ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 03.08. | Wells Fargo initiates Pyxis Oncology stock with overweight rating | 7 | Investing.com | ||
| 06.07. | H.C. Wainwright bestätigt Kaufempfehlung für Pyxis Oncology Aktie | 24 | Investing.com Deutsch | ||
| 06.07. | H.C. Wainwright reiterates Pyxis Oncology stock rating at buy | 3 | Investing.com | ||
| 02.07. | Pyxis Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | Leerink cuts Pyxis Oncology stock price target on valuation | 2 | Investing.com | ||
| 30.06. | Pyxis Oncology raises $50 million in private placement | 5 | Investing.com | ||
| 30.06. | Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones | 604 | GlobeNewswire (Europe) | Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap Company now expects updated Phase... ► Artikel lesen | |
| 15.06. | Pyxis Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Pyxis Oncology, Inc. - 10-Q, Quarterly Report | 6 | SEC Filings | ||
| 14.05. | Pyxis Oncology GAAP EPS of -$0.37 misses by $0.01 | 8 | Seeking Alpha | ||
| 14.05. | Pyxis Oncology, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 07.05. | Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer | 230 | GlobeNewswire (Europe) | BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment... ► Artikel lesen | |
| 17.04. | Pyxis Oncology legt vielversprechende präklinische Daten für MICVO bei Kopf- und Halskrebs vor | 12 | Investing.com Deutsch | ||
| 17.04. | Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 | 2 | GlobeNewswire (USA) | ||
| 24.03. | Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data | 10 | Investing.com | ||
| 24.03. | H.C. Wainwright reiterates Buy on Pyxis Oncology stock, $7 target | 2 | Investing.com | ||
| 24.03. | Stifel cuts Pyxis Oncology stock price target on financing assumptions | 15 | Investing.com |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| EVOTEC | 3,348 | -1,06 % | Evotec-Aktie: Fällt jetzt die 3,00 €-Marke? | Die Evotec-Aktie befindet sich weiterhin tief im Abwärtstrend und notiert inzwischen rund -93% unter ihrem Allzeithoch. Damit hat die Biotech-Aktie über Jahre hinweg massiv an Wert verloren. Gleichzeitig... ► Artikel lesen | |
| BB BIOTECH | 59,40 | -0,17 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| VALNEVA | 2,798 | +0,76 % | Katalysator voraus: Valneva (ISIN: FR0004056851) setzt auf Q3-Shigella-Daten | ||
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| BIOGEN | 187,62 | -0,51 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 49,360 | -0,85 % | CRISPR Therapeutics legt positive Einjahresdaten für Gentherapie CTX310 vor | ||
| PALATIN TECHNOLOGIES | 10,500 | +0,19 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 1,162 | +1,57 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| BAVARIAN NORDIC | 28,400 | -0,21 % | Bavarian Nordic A/S: Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such | ||
| TEMPUS AI | 55,25 | -0,04 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? | ||
| BIOCRYST PHARMACEUTICALS | 8,450 | -0,35 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen |
PYXIS ONCOLOGY INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,230 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PYXIS ONCOLOGY INC finden Sie auf Wallstreet Online.